Eubiotics Global Market Report 2024

The global eubiotics market has grown strongly in recent years. It will grow from $5.37 billion in 2023 to $5.85 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. Historical growth can be attributed to heightened consumer awareness regarding healthy diets, a focus on improving livestock health and performance, concerns surrounding antibiotic resistance, the rising consumption of meat, and substantial investments in research and development efforts.

The global eubiotics market is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth in the forecast period is driven by several factors, including the emergence of eubiotic blends, a noticeable trend towards sustainable agriculture, the expansion of the dairy industry, application in horse nutrition, and the integration of prebiotics and postbiotics in various sectors. Major trends expected during this period involve the replacement of antibiotic growth promoters (AGPs) with prebiotics and probiotics, increased regulatory emphasis on reducing antibiotics, advancements in microbial solutions, the adoption of sustainable and eco-friendly practices, the expansion of applications in aquaculture, and the facilitation of collaborations and partnerships within the industry.

The expanding population of livestock animals, driven by their utilization for commercial purposes such as milk, eggs, meat, and fiber products, is anticipated to drive the growth of the eubiotics market. Notably, the hog and pig population in Brazil increased by 3.2% to reach 42.25 million in 2021. This trend of increased use of livestock animals for commercial gain is projected to fuel the eubiotics market's growth in the near future.

The increasing demand for high-quality animal feeds, which are tailored to meet specific dietary requirements and ensure optimal animal health and productivity, is a significant driver for the eubiotics market. Eubiotics play a crucial role in modern animal nutrition by supporting animal health, reducing reliance on antibiotics, and promoting sustainable livestock production. Forecasts by the American Feed Industry Association suggest a significant increase in animal food consumption by 2025, reaching 263.1 million tons, emphasizing the rising need for quality animal feeds and thus, eubiotics.

The eubiotics market is witnessing a trend of product innovation, particularly in feed additives that enhance animal performance by improving gut health. For instance, Chr. Hansen Holding A/S introduced Bacillus, a probiotic product enriched with high-quality digestive enzymes that enhance the gut health of animals. This innovation signifies a push towards advanced nutrition in the eubiotics industry.

Major companies are directing their efforts toward developing innovative products like prebiotic fiber to maintain a competitive edge in the eubiotics market. Alltech launched Microbuild, a cutting-edge prebiotic fiber designed to support robust gut health in pets. Microbuild stimulates the growth of beneficial gut bacteria, enhancing nutrient absorption, maintaining intestinal integrity, and fortifying the immune system. This innovation underscores the intersection of genetics and nutrition in the development of advanced eubiotics like Microbuild, which actively contribute to improving pets' overall well-being and health.

In July 2021, Royal DSM, a leading Dutch-based company focused on sustainable living, health, and nutrition, completed the acquisition of Midori USA, Inc. for $63 million. This strategic move enables Royal DSM to bolster its portfolio in the development of eubiotics, fortifying its expertise and offerings in this domain. Midori USA, Inc., a biotechnology start-up, specializes in the creation of targeted eubiotics designed to enhance animal health while also delivering positive environmental benefits. With this acquisition, Royal DSM expands its capabilities and reinforces its commitment to developing innovative solutions that promote animal well-being and contribute to sustainability within the agriculture and animal nutrition sectors.

Major companies operating in the eubiotics market report are BASF SE, Koninklijke DSM NV, Lallemand Inc., Novus International Inc., Chr Hansen Holding A/S, Cargill Inc., E I du Pont de Nemours and Company, Calpis Co. Ltd., Lesaffre Group, Kemin Industries Inc., Evonik Industries AG, Archer Daniels Midland Company, Beneo GmbH, BioResource International Inc., Biomin Holding GmbH, Bluestar Adisseo Company, Dupont Nutrition & Biosciences, Nutreco NV, Pancosma SA, Provimi Holding BV, Synbio Tech Inc., Vetagro SpA, Wacker Chemie AG, Zinpro Corporation, Alltech Inc., Danisco Animal & Nutrition, Impextraco NV, Nuscience Group, and Olmix Group.

Europe was the largest region in the eubiotics market in 2023. The regions covered in the eubiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eubiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of eubiotics encompass probiotics, prebiotics, organic acids, essential oils, and enzymes. Probiotics consist of live microorganisms that contribute to overall health, bolstering immunity and promoting digestive well-being. These microorganisms aid in improving immunity, digestion, gut health, and reducing microbial contamination. Eubiotics are available in various treatment forms such as dry and liquid formulations tailored for applications in livestock including cattle, poultry, swine, aquaculture, and other animals, catering to needs related to gut and digestive health, overall wellness, and immunity support in animals.

This report provides eubiotics market statistics, including the eubiotics industry's global market size, regional shares, competitors with a eubiotics market share, detailed eubiotics market segments, market trends and opportunities, and any further data you may need to thrive in the eubiotics industry. This eubiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eubiotics market consists of sales of lactobacilli, bifidobacterium, streptococcus, fructo-oligosaccharides (FOS), inulin, galacto-oligosaccharides (GOS), and mannan-oligosaccharides (MOS). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.